ATM and prostate carcinoma: Overall, the data suggest that the antitumour activity of olaparib in metastatic castration-resistant prostate cancer with ATM loss is less than that for BRCA-altered tumours; nevertheless, a subset of patients with ATM-altered metastatic castration-resistant prostate cancer appear to derive benefit.